TMPRSS2 and Familial prostate cancer: Cases in this study were population-based unlike several previous TMPRSS2-ERG studies [4,5,18,19], there was a mean surveillance period of 11.6 years after diagnosis, and prostate cancer-specific death was confirmed by death certificate.